Omeros (NASDAQ:OMER) Cut to Sell at BidaskClub

BidaskClub downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report issued on Tuesday, BidAskClub reports.

Several other analysts have also recently issued reports on the company. Wedbush set a $20.00 price objective on Plymouth Industrial Reit and gave the stock a buy rating in a report on Monday, May 20th. ValuEngine cut Yirendai from a sell rating to a strong sell rating in a report on Wednesday, June 26th. Zacks Investment Research raised Garrett Motion from a sell rating to a hold rating in a report on Friday, May 10th. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a buy rating in a report on Tuesday, May 28th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $71.00 price objective on shares of ExlService in a report on Monday, May 6th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Omeros presently has an average rating of Hold and an average target price of $25.80.

NASDAQ OMER opened at $15.70 on Tuesday. The business has a 50 day simple moving average of $16.48. Omeros has a 12 month low of $10.30 and a 12 month high of $27.00.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The company had revenue of $21.80 million during the quarter, compared to the consensus estimate of $23.18 million. The company’s quarterly revenue was up 1271.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.62) earnings per share. As a group, analysts anticipate that Omeros will post -1.51 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Rhumbline Advisers increased its position in shares of Omeros by 73.3% during the 4th quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock valued at $805,000 after purchasing an additional 30,547 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Omeros by 31.7% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,250 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 4,150 shares during the last quarter. First Trust Advisors LP bought a new position in shares of Omeros during the 4th quarter valued at approximately $879,000. California Public Employees Retirement System increased its position in shares of Omeros by 6.7% during the 4th quarter. California Public Employees Retirement System now owns 49,310 shares of the biopharmaceutical company’s stock valued at $549,000 after purchasing an additional 3,110 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Omeros by 0.8% during the 4th quarter. BlackRock Inc. now owns 3,989,206 shares of the biopharmaceutical company’s stock valued at $44,439,000 after purchasing an additional 31,270 shares during the last quarter. 52.12% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Growth and Income Funds

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.